What is the projected market valuation for the Hospital and Nursing Home Probiotic Market in 2035?

The projected market valuation for the Hospital and Nursing Home Probiotic Market in 2035 is 7.226 USD Billion. Read More

What was the market valuation for the Hospital and Nursing Home Probiotic Market in 2024?

The overall market valuation for the Hospital and Nursing Home Probiotic Market was 2.939 USD Billion in 2024. Read More

What is the expected CAGR for the Hospital and Nursing Home Probiotic Market from 2025 to 2035?

The expected CAGR for the Hospital and Nursing Home Probiotic Market during the forecast period 2025 - 2035 is 8.52%. Read More

Which companies are considered key players in the Hospital and Nursing Home Probiotic Market?

Key players in the market include Danone, Nestle, Procter & Gamble, Kerry Group, Chr. Hansen, Lactalis Ingredients, Synlogic, BioCare Copenhagen, and ProbioFerm. Read More

What are the projected revenues for probiotic capsules in 2025?

Probiotic capsules are projected to generate revenues of 1.978 USD Billion in 2025. Read More

How do the revenues for probiotic powders compare to those for probiotic liquids in 2025?

In 2025, probiotic powders are expected to generate 1.368 USD Billion, which is equal to the projected revenue for probiotic liquids. Read More

What is the expected revenue for probiotics targeting elderly patients in 2025?

Probiotics targeting elderly patients are projected to generate revenues of 1.5 USD Billion in 2025. Read More

Which distribution channel is expected to yield the highest revenue in 2025?

Hospitals are expected to yield the highest revenue in 2025, with projections of 1.978 USD Billion. Read More

What is the anticipated revenue for probiotic yogurt in 2025?

Probiotic yogurt is anticipated to generate revenues of 1.226 USD Billion in 2025. Read More

What are the projected revenues for probiotic products aimed at patients with gastrointestinal disorders in 2025?

Probiotic products aimed at patients with gastrointestinal disorders are projected to generate revenues of 1.526 USD Billion in 2025. Read More

Hospital and Nursing Home Probiotic Market

ID: MRFR/FnB/30179-HCR

128 Pages

Varsha More

Last Updated: April 06, 2026

Hospital and Nursing Home Probiotic Market Size, Share, Industry Trend & Analysis Research Report By Probiotic Formulation Type (Capsules, Powder, Liquid, Soft Chew, Probiotic Yogurt), By Target Patient Group (Infants, Adults, Elderly, Immunocompromised Patients, Patients with Gastrointestinal Disorders), By Indication (Antibiotic-Associated Diarrhea, Irritable Bowel Syndrome, Clostridium difficile Infection, Inflammatory Bowel Disease, General Gut Health), By Distribution Channel (Hospitals, Nursing Homes, Pharmacies, Online Retail, Healthcare Facilities), By Product Source (Bacterial Strains, Yeast Strains, Synbiotics, Fermented Foods) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Forecast to 2035.

Hospital and Nursing Home Probiotic Market Infographic

Summary Table of Contents Segmentation Download PDF

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1.1 EXECUTIVE SUMMARY
1.1.1 Market Overview
1.1.2 Key Findings
1.1.3 Market Segmentation
1.1.4 Competitive Landscape
1.1.5 Challenges and Opportunities
1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
2.1 MARKET INTRODUCTION
2.1.1 Definition
2.1.2 Scope of the study
2.1.2.1 Research Objective
2.1.2.2 Assumption
2.1.2.3 Limitations
2.2 RESEARCH METHODOLOGY
2.2.1 Overview
2.2.2 Data Mining
2.2.3 Secondary Research
2.2.4 Primary Research
2.2.4.1 Primary Interviews and Information Gathering Process
2.2.4.2 Breakdown of Primary Respondents
2.2.5 Forecasting Model
2.2.6 Market Size Estimation
2.2.6.1 Bottom-Up Approach
2.2.6.2 Top-Down Approach
2.2.7 Data Triangulation
2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
3.1 MARKET DYNAMICS
3.1.1 Overview
3.1.2 Drivers
3.1.3 Restraints
3.1.4 Opportunities
3.2 MARKET FACTOR ANALYSIS
3.2.1 Value chain Analysis
3.2.2 Porter's Five Forces Analysis
3.2.2.1 Bargaining Power of Suppliers
3.2.2.2 Bargaining Power of Buyers
3.2.2.3 Threat of New Entrants
3.2.2.4 Threat of Substitutes
3.2.2.5 Intensity of Rivalry
3.2.3 COVID-19 Impact Analysis
3.2.3.1 Market Impact Analysis
3.2.3.2 Regional Impact
3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
4.1 Food, Beverages & Nutrition, BY Probiotic Formulation Type (USD Billion)
4.1.1 Capsules
4.1.2 Powder
4.1.3 Liquid
4.1.4 Soft Chew
4.1.5 Probiotic Yogurt
4.2 Food, Beverages & Nutrition, BY Target Patient Group (USD Billion)
4.2.1 Infants
4.2.2 Adults
4.2.3 Elderly
4.2.4 Immunocompromised Patients
4.2.5 Patients with Gastrointestinal Disorders
4.3 Food, Beverages & Nutrition, BY Indication (USD Billion)
4.3.1 Antibiotic-Associated Diarrhea
4.3.2 Irritable Bowel Syndrome
4.3.3 Clostridium difficile Infection
4.3.4 Inflammatory Bowel Disease
4.3.5 General Gut Health
4.4 Food, Beverages & Nutrition, BY Distribution Channel (USD Billion)
4.4.1 Hospitals
4.4.2 Nursing Homes
4.4.3 Pharmacies
4.4.4 Online Retail
4.4.5 Healthcare Facilities
4.5 Food, Beverages & Nutrition, BY Product Source (USD Billion)
4.5.1 Bacterial Strains
4.5.2 Yeast Strains
4.5.3 Synbiotics
4.5.4 Fermented Foods
4.6 Food, Beverages & Nutrition, BY Region (USD Billion)
4.6.1 North America
4.6.1.1 US
4.6.1.2 Canada
4.6.2 Europe
4.6.2.1 Germany
4.6.2.2 UK
4.6.2.3 France
4.6.2.4 Russia
4.6.2.5 Italy
4.6.2.6 Spain
4.6.2.7 Rest of Europe
4.6.3 APAC
4.6.3.1 China
4.6.3.2 India
4.6.3.3 Japan
4.6.3.4 South Korea
4.6.3.5 Malaysia
4.6.3.6 Thailand
4.6.3.7 Indonesia
4.6.3.8 Rest of APAC
4.6.4 South America
4.6.4.1 Brazil
4.6.4.2 Mexico
4.6.4.3 Argentina
4.6.4.4 Rest of South America
4.6.5 MEA
4.6.5.1 GCC Countries
4.6.5.2 South Africa
4.6.5.3 Rest of MEA
5 SECTION V: COMPETITIVE ANALYSIS
5.1 Competitive Landscape
5.1.1 Overview
5.1.2 Competitive Analysis
5.1.3 Market share Analysis
5.1.4 Major Growth Strategy in the Food, Beverages & Nutrition
5.1.5 Competitive Benchmarking
5.1.6 Leading Players in Terms of Number of Developments in the Food, Beverages & Nutrition
5.1.7 Key developments and growth strategies
5.1.7.1 New Product Launch/Service Deployment
5.1.7.2 Merger & Acquisitions
5.1.7.3 Joint Ventures
5.1.8 Major Players Financial Matrix
5.1.8.1 Sales and Operating Income
5.1.8.2 Major Players R&D Expenditure. 2023
5.2 Company Profiles
5.2.1 Danone (FR)
5.2.1.1 Financial Overview
5.2.1.2 Products Offered
5.2.1.3 Key Developments
5.2.1.4 SWOT Analysis
5.2.1.5 Key Strategies
5.2.2 Nestle (CH)
5.2.2.1 Financial Overview
5.2.2.2 Products Offered
5.2.2.3 Key Developments
5.2.2.4 SWOT Analysis
5.2.2.5 Key Strategies
5.2.3 Procter & Gamble (US)
5.2.3.1 Financial Overview
5.2.3.2 Products Offered
5.2.3.3 Key Developments
5.2.3.4 SWOT Analysis
5.2.3.5 Key Strategies
5.2.4 Kerry Group (IE)
5.2.4.1 Financial Overview
5.2.4.2 Products Offered
5.2.4.3 Key Developments
5.2.4.4 SWOT Analysis
5.2.4.5 Key Strategies
5.2.5 Chr. Hansen (DK)
5.2.5.1 Financial Overview
5.2.5.2 Products Offered
5.2.5.3 Key Developments
5.2.5.4 SWOT Analysis
5.2.5.5 Key Strategies
5.2.6 Lactalis Ingredients (FR)
5.2.6.1 Financial Overview
5.2.6.2 Products Offered
5.2.6.3 Key Developments
5.2.6.4 SWOT Analysis
5.2.6.5 Key Strategies
5.2.7 Synlogic (US)
5.2.7.1 Financial Overview
5.2.7.2 Products Offered
5.2.7.3 Key Developments
5.2.7.4 SWOT Analysis
5.2.7.5 Key Strategies
5.2.8 BioCare Copenhagen (DK)
5.2.8.1 Financial Overview
5.2.8.2 Products Offered
5.2.8.3 Key Developments
5.2.8.4 SWOT Analysis
5.2.8.5 Key Strategies
5.2.9 ProbioFerm (DE)
5.2.9.1 Financial Overview
5.2.9.2 Products Offered
5.2.9.3 Key Developments
5.2.9.4 SWOT Analysis
5.2.9.5 Key Strategies
5.3 Appendix
5.3.1 References
5.3.2 Related Reports
6 LIST OF FIGURES
6.1 MARKET SYNOPSIS
6.2 NORTH AMERICA MARKET ANALYSIS
6.3 US MARKET ANALYSIS BY PROBIOTIC FORMULATION TYPE
6.4 US MARKET ANALYSIS BY TARGET PATIENT GROUP
6.5 US MARKET ANALYSIS BY INDICATION
6.6 US MARKET ANALYSIS BY DISTRIBUTION CHANNEL
6.7 US MARKET ANALYSIS BY PRODUCT SOURCE
6.8 CANADA MARKET ANALYSIS BY PROBIOTIC FORMULATION TYPE
6.9 CANADA MARKET ANALYSIS BY TARGET PATIENT GROUP
6.10 CANADA MARKET ANALYSIS BY INDICATION
6.11 CANADA MARKET ANALYSIS BY DISTRIBUTION CHANNEL
6.12 CANADA MARKET ANALYSIS BY PRODUCT SOURCE
6.13 EUROPE MARKET ANALYSIS
6.14 GERMANY MARKET ANALYSIS BY PROBIOTIC FORMULATION TYPE
6.15 GERMANY MARKET ANALYSIS BY TARGET PATIENT GROUP
6.16 GERMANY MARKET ANALYSIS BY INDICATION
6.17 GERMANY MARKET ANALYSIS BY DISTRIBUTION CHANNEL
6.18 GERMANY MARKET ANALYSIS BY PRODUCT SOURCE
6.19 UK MARKET ANALYSIS BY PROBIOTIC FORMULATION TYPE
6.20 UK MARKET ANALYSIS BY TARGET PATIENT GROUP
6.21 UK MARKET ANALYSIS BY INDICATION
6.22 UK MARKET ANALYSIS BY DISTRIBUTION CHANNEL
6.23 UK MARKET ANALYSIS BY PRODUCT SOURCE
6.24 FRANCE MARKET ANALYSIS BY PROBIOTIC FORMULATION TYPE
6.25 FRANCE MARKET ANALYSIS BY TARGET PATIENT GROUP
6.26 FRANCE MARKET ANALYSIS BY INDICATION
6.27 FRANCE MARKET ANALYSIS BY DISTRIBUTION CHANNEL
6.28 FRANCE MARKET ANALYSIS BY PRODUCT SOURCE
6.29 RUSSIA MARKET ANALYSIS BY PROBIOTIC FORMULATION TYPE
6.30 RUSSIA MARKET ANALYSIS BY TARGET PATIENT GROUP
6.31 RUSSIA MARKET ANALYSIS BY INDICATION
6.32 RUSSIA MARKET ANALYSIS BY DISTRIBUTION CHANNEL
6.33 RUSSIA MARKET ANALYSIS BY PRODUCT SOURCE
6.34 ITALY MARKET ANALYSIS BY PROBIOTIC FORMULATION TYPE
6.35 ITALY MARKET ANALYSIS BY TARGET PATIENT GROUP
6.36 ITALY MARKET ANALYSIS BY INDICATION
6.37 ITALY MARKET ANALYSIS BY DISTRIBUTION CHANNEL
6.38 ITALY MARKET ANALYSIS BY PRODUCT SOURCE
6.39 SPAIN MARKET ANALYSIS BY PROBIOTIC FORMULATION TYPE
6.40 SPAIN MARKET ANALYSIS BY TARGET PATIENT GROUP
6.41 SPAIN MARKET ANALYSIS BY INDICATION
6.42 SPAIN MARKET ANALYSIS BY DISTRIBUTION CHANNEL
6.43 SPAIN MARKET ANALYSIS BY PRODUCT SOURCE
6.44 REST OF EUROPE MARKET ANALYSIS BY PROBIOTIC FORMULATION TYPE
6.45 REST OF EUROPE MARKET ANALYSIS BY TARGET PATIENT GROUP
6.46 REST OF EUROPE MARKET ANALYSIS BY INDICATION
6.47 REST OF EUROPE MARKET ANALYSIS BY DISTRIBUTION CHANNEL
6.48 REST OF EUROPE MARKET ANALYSIS BY PRODUCT SOURCE
6.49 APAC MARKET ANALYSIS
6.50 CHINA MARKET ANALYSIS BY PROBIOTIC FORMULATION TYPE
6.51 CHINA MARKET ANALYSIS BY TARGET PATIENT GROUP
6.52 CHINA MARKET ANALYSIS BY INDICATION
6.53 CHINA MARKET ANALYSIS BY DISTRIBUTION CHANNEL
6.54 CHINA MARKET ANALYSIS BY PRODUCT SOURCE
6.55 INDIA MARKET ANALYSIS BY PROBIOTIC FORMULATION TYPE
6.56 INDIA MARKET ANALYSIS BY TARGET PATIENT GROUP
6.57 INDIA MARKET ANALYSIS BY INDICATION
6.58 INDIA MARKET ANALYSIS BY DISTRIBUTION CHANNEL
6.59 INDIA MARKET ANALYSIS BY PRODUCT SOURCE
6.60 JAPAN MARKET ANALYSIS BY PROBIOTIC FORMULATION TYPE
6.61 JAPAN MARKET ANALYSIS BY TARGET PATIENT GROUP
6.62 JAPAN MARKET ANALYSIS BY INDICATION
6.63 JAPAN MARKET ANALYSIS BY DISTRIBUTION CHANNEL
6.64 JAPAN MARKET ANALYSIS BY PRODUCT SOURCE
6.65 SOUTH KOREA MARKET ANALYSIS BY PROBIOTIC FORMULATION TYPE
6.66 SOUTH KOREA MARKET ANALYSIS BY TARGET PATIENT GROUP
6.67 SOUTH KOREA MARKET ANALYSIS BY INDICATION
6.68 SOUTH KOREA MARKET ANALYSIS BY DISTRIBUTION CHANNEL
6.69 SOUTH KOREA MARKET ANALYSIS BY PRODUCT SOURCE
6.70 MALAYSIA MARKET ANALYSIS BY PROBIOTIC FORMULATION TYPE
6.71 MALAYSIA MARKET ANALYSIS BY TARGET PATIENT GROUP
6.72 MALAYSIA MARKET ANALYSIS BY INDICATION
6.73 MALAYSIA MARKET ANALYSIS BY DISTRIBUTION CHANNEL
6.74 MALAYSIA MARKET ANALYSIS BY PRODUCT SOURCE
6.75 THAILAND MARKET ANALYSIS BY PROBIOTIC FORMULATION TYPE
6.76 THAILAND MARKET ANALYSIS BY TARGET PATIENT GROUP
6.77 THAILAND MARKET ANALYSIS BY INDICATION
6.78 THAILAND MARKET ANALYSIS BY DISTRIBUTION CHANNEL
6.79 THAILAND MARKET ANALYSIS BY PRODUCT SOURCE
6.80 INDONESIA MARKET ANALYSIS BY PROBIOTIC FORMULATION TYPE
6.81 INDONESIA MARKET ANALYSIS BY TARGET PATIENT GROUP
6.82 INDONESIA MARKET ANALYSIS BY INDICATION
6.83 INDONESIA MARKET ANALYSIS BY DISTRIBUTION CHANNEL
6.84 INDONESIA MARKET ANALYSIS BY PRODUCT SOURCE
6.85 REST OF APAC MARKET ANALYSIS BY PROBIOTIC FORMULATION TYPE
6.86 REST OF APAC MARKET ANALYSIS BY TARGET PATIENT GROUP
6.87 REST OF APAC MARKET ANALYSIS BY INDICATION
6.88 REST OF APAC MARKET ANALYSIS BY DISTRIBUTION CHANNEL
6.89 REST OF APAC MARKET ANALYSIS BY PRODUCT SOURCE
6.90 SOUTH AMERICA MARKET ANALYSIS
6.91 BRAZIL MARKET ANALYSIS BY PROBIOTIC FORMULATION TYPE
6.92 BRAZIL MARKET ANALYSIS BY TARGET PATIENT GROUP
6.93 BRAZIL MARKET ANALYSIS BY INDICATION
6.94 BRAZIL MARKET ANALYSIS BY DISTRIBUTION CHANNEL
6.95 BRAZIL MARKET ANALYSIS BY PRODUCT SOURCE
6.96 MEXICO MARKET ANALYSIS BY PROBIOTIC FORMULATION TYPE
6.97 MEXICO MARKET ANALYSIS BY TARGET PATIENT GROUP
6.98 MEXICO MARKET ANALYSIS BY INDICATION
6.99 MEXICO MARKET ANALYSIS BY DISTRIBUTION CHANNEL
6.100 MEXICO MARKET ANALYSIS BY PRODUCT SOURCE
6.101 ARGENTINA MARKET ANALYSIS BY PROBIOTIC FORMULATION TYPE
6.102 ARGENTINA MARKET ANALYSIS BY TARGET PATIENT GROUP
6.103 ARGENTINA MARKET ANALYSIS BY INDICATION
6.104 ARGENTINA MARKET ANALYSIS BY DISTRIBUTION CHANNEL
6.105 ARGENTINA MARKET ANALYSIS BY PRODUCT SOURCE
6.106 REST OF SOUTH AMERICA MARKET ANALYSIS BY PROBIOTIC FORMULATION TYPE
6.107 REST OF SOUTH AMERICA MARKET ANALYSIS BY TARGET PATIENT GROUP
6.108 REST OF SOUTH AMERICA MARKET ANALYSIS BY INDICATION
6.109 REST OF SOUTH AMERICA MARKET ANALYSIS BY DISTRIBUTION CHANNEL
6.110 REST OF SOUTH AMERICA MARKET ANALYSIS BY PRODUCT SOURCE
6.111 MEA MARKET ANALYSIS
6.112 GCC COUNTRIES MARKET ANALYSIS BY PROBIOTIC FORMULATION TYPE
6.113 GCC COUNTRIES MARKET ANALYSIS BY TARGET PATIENT GROUP
6.114 GCC COUNTRIES MARKET ANALYSIS BY INDICATION
6.115 GCC COUNTRIES MARKET ANALYSIS BY DISTRIBUTION CHANNEL
6.116 GCC COUNTRIES MARKET ANALYSIS BY PRODUCT SOURCE
6.117 SOUTH AFRICA MARKET ANALYSIS BY PROBIOTIC FORMULATION TYPE
6.118 SOUTH AFRICA MARKET ANALYSIS BY TARGET PATIENT GROUP
6.119 SOUTH AFRICA MARKET ANALYSIS BY INDICATION
6.120 SOUTH AFRICA MARKET ANALYSIS BY DISTRIBUTION CHANNEL
6.121 SOUTH AFRICA MARKET ANALYSIS BY PRODUCT SOURCE
6.122 REST OF MEA MARKET ANALYSIS BY PROBIOTIC FORMULATION TYPE
6.123 REST OF MEA MARKET ANALYSIS BY TARGET PATIENT GROUP
6.124 REST OF MEA MARKET ANALYSIS BY INDICATION
6.125 REST OF MEA MARKET ANALYSIS BY DISTRIBUTION CHANNEL
6.126 REST OF MEA MARKET ANALYSIS BY PRODUCT SOURCE
6.127 KEY BUYING CRITERIA OF FOOD, BEVERAGES & NUTRITION
6.128 RESEARCH PROCESS OF MRFR
6.129 DRO ANALYSIS OF FOOD, BEVERAGES & NUTRITION
6.130 DRIVERS IMPACT ANALYSIS: FOOD, BEVERAGES & NUTRITION
6.131 RESTRAINTS IMPACT ANALYSIS: FOOD, BEVERAGES & NUTRITION
6.132 SUPPLY / VALUE CHAIN: FOOD, BEVERAGES & NUTRITION
6.133 FOOD, BEVERAGES & NUTRITION, BY PROBIOTIC FORMULATION TYPE, 2024 (% SHARE)
6.134 FOOD, BEVERAGES & NUTRITION, BY PROBIOTIC FORMULATION TYPE, 2024 TO 2035 (USD Billion)
6.135 FOOD, BEVERAGES & NUTRITION, BY TARGET PATIENT GROUP, 2024 (% SHARE)
6.136 FOOD, BEVERAGES & NUTRITION, BY TARGET PATIENT GROUP, 2024 TO 2035 (USD Billion)
6.137 FOOD, BEVERAGES & NUTRITION, BY INDICATION, 2024 (% SHARE)
6.138 FOOD, BEVERAGES & NUTRITION, BY INDICATION, 2024 TO 2035 (USD Billion)
6.139 FOOD, BEVERAGES & NUTRITION, BY DISTRIBUTION CHANNEL, 2024 (% SHARE)
6.140 FOOD, BEVERAGES & NUTRITION, BY DISTRIBUTION CHANNEL, 2024 TO 2035 (USD Billion)
6.141 FOOD, BEVERAGES & NUTRITION, BY PRODUCT SOURCE, 2024 (% SHARE)
6.142 FOOD, BEVERAGES & NUTRITION, BY PRODUCT SOURCE, 2024 TO 2035 (USD Billion)
6.143 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
7.1 LIST OF ASSUMPTIONS
7.1.1
7.2 North America MARKET SIZE ESTIMATES; FORECAST
7.2.1 BY PROBIOTIC FORMULATION TYPE, 2025-2035 (USD Billion)
7.2.2 BY TARGET PATIENT GROUP, 2025-2035 (USD Billion)
7.2.3 BY INDICATION, 2025-2035 (USD Billion)
7.2.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
7.2.5 BY PRODUCT SOURCE, 2025-2035 (USD Billion)
7.3 US MARKET SIZE ESTIMATES; FORECAST
7.3.1 BY PROBIOTIC FORMULATION TYPE, 2025-2035 (USD Billion)
7.3.2 BY TARGET PATIENT GROUP, 2025-2035 (USD Billion)
7.3.3 BY INDICATION, 2025-2035 (USD Billion)
7.3.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
7.3.5 BY PRODUCT SOURCE, 2025-2035 (USD Billion)
7.4 Canada MARKET SIZE ESTIMATES; FORECAST
7.4.1 BY PROBIOTIC FORMULATION TYPE, 2025-2035 (USD Billion)
7.4.2 BY TARGET PATIENT GROUP, 2025-2035 (USD Billion)
7.4.3 BY INDICATION, 2025-2035 (USD Billion)
7.4.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
7.4.5 BY PRODUCT SOURCE, 2025-2035 (USD Billion)
7.5 Europe MARKET SIZE ESTIMATES; FORECAST
7.5.1 BY PROBIOTIC FORMULATION TYPE, 2025-2035 (USD Billion)
7.5.2 BY TARGET PATIENT GROUP, 2025-2035 (USD Billion)
7.5.3 BY INDICATION, 2025-2035 (USD Billion)
7.5.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
7.5.5 BY PRODUCT SOURCE, 2025-2035 (USD Billion)
7.6 Germany MARKET SIZE ESTIMATES; FORECAST
7.6.1 BY PROBIOTIC FORMULATION TYPE, 2025-2035 (USD Billion)
7.6.2 BY TARGET PATIENT GROUP, 2025-2035 (USD Billion)
7.6.3 BY INDICATION, 2025-2035 (USD Billion)
7.6.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
7.6.5 BY PRODUCT SOURCE, 2025-2035 (USD Billion)
7.7 UK MARKET SIZE ESTIMATES; FORECAST
7.7.1 BY PROBIOTIC FORMULATION TYPE, 2025-2035 (USD Billion)
7.7.2 BY TARGET PATIENT GROUP, 2025-2035 (USD Billion)
7.7.3 BY INDICATION, 2025-2035 (USD Billion)
7.7.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
7.7.5 BY PRODUCT SOURCE, 2025-2035 (USD Billion)
7.8 France MARKET SIZE ESTIMATES; FORECAST
7.8.1 BY PROBIOTIC FORMULATION TYPE, 2025-2035 (USD Billion)
7.8.2 BY TARGET PATIENT GROUP, 2025-2035 (USD Billion)
7.8.3 BY INDICATION, 2025-2035 (USD Billion)
7.8.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
7.8.5 BY PRODUCT SOURCE, 2025-2035 (USD Billion)
7.9 Russia MARKET SIZE ESTIMATES; FORECAST
7.9.1 BY PROBIOTIC FORMULATION TYPE, 2025-2035 (USD Billion)
7.9.2 BY TARGET PATIENT GROUP, 2025-2035 (USD Billion)
7.9.3 BY INDICATION, 2025-2035 (USD Billion)
7.9.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
7.9.5 BY PRODUCT SOURCE, 2025-2035 (USD Billion)
7.10 Italy MARKET SIZE ESTIMATES; FORECAST
7.10.1 BY PROBIOTIC FORMULATION TYPE, 2025-2035 (USD Billion)
7.10.2 BY TARGET PATIENT GROUP, 2025-2035 (USD Billion)
7.10.3 BY INDICATION, 2025-2035 (USD Billion)
7.10.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
7.10.5 BY PRODUCT SOURCE, 2025-2035 (USD Billion)
7.11 Spain MARKET SIZE ESTIMATES; FORECAST
7.11.1 BY PROBIOTIC FORMULATION TYPE, 2025-2035 (USD Billion)
7.11.2 BY TARGET PATIENT GROUP, 2025-2035 (USD Billion)
7.11.3 BY INDICATION, 2025-2035 (USD Billion)
7.11.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
7.11.5 BY PRODUCT SOURCE, 2025-2035 (USD Billion)
7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST
7.12.1 BY PROBIOTIC FORMULATION TYPE, 2025-2035 (USD Billion)
7.12.2 BY TARGET PATIENT GROUP, 2025-2035 (USD Billion)
7.12.3 BY INDICATION, 2025-2035 (USD Billion)
7.12.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
7.12.5 BY PRODUCT SOURCE, 2025-2035 (USD Billion)
7.13 APAC MARKET SIZE ESTIMATES; FORECAST
7.13.1 BY PROBIOTIC FORMULATION TYPE, 2025-2035 (USD Billion)
7.13.2 BY TARGET PATIENT GROUP, 2025-2035 (USD Billion)
7.13.3 BY INDICATION, 2025-2035 (USD Billion)
7.13.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
7.13.5 BY PRODUCT SOURCE, 2025-2035 (USD Billion)
7.14 China MARKET SIZE ESTIMATES; FORECAST
7.14.1 BY PROBIOTIC FORMULATION TYPE, 2025-2035 (USD Billion)
7.14.2 BY TARGET PATIENT GROUP, 2025-2035 (USD Billion)
7.14.3 BY INDICATION, 2025-2035 (USD Billion)
7.14.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
7.14.5 BY PRODUCT SOURCE, 2025-2035 (USD Billion)
7.15 India MARKET SIZE ESTIMATES; FORECAST
7.15.1 BY PROBIOTIC FORMULATION TYPE, 2025-2035 (USD Billion)
7.15.2 BY TARGET PATIENT GROUP, 2025-2035 (USD Billion)
7.15.3 BY INDICATION, 2025-2035 (USD Billion)
7.15.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
7.15.5 BY PRODUCT SOURCE, 2025-2035 (USD Billion)
7.16 Japan MARKET SIZE ESTIMATES; FORECAST
7.16.1 BY PROBIOTIC FORMULATION TYPE, 2025-2035 (USD Billion)
7.16.2 BY TARGET PATIENT GROUP, 2025-2035 (USD Billion)
7.16.3 BY INDICATION, 2025-2035 (USD Billion)
7.16.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
7.16.5 BY PRODUCT SOURCE, 2025-2035 (USD Billion)
7.17 South Korea MARKET SIZE ESTIMATES; FORECAST
7.17.1 BY PROBIOTIC FORMULATION TYPE, 2025-2035 (USD Billion)
7.17.2 BY TARGET PATIENT GROUP, 2025-2035 (USD Billion)
7.17.3 BY INDICATION, 2025-2035 (USD Billion)
7.17.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
7.17.5 BY PRODUCT SOURCE, 2025-2035 (USD Billion)
7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST
7.18.1 BY PROBIOTIC FORMULATION TYPE, 2025-2035 (USD Billion)
7.18.2 BY TARGET PATIENT GROUP, 2025-2035 (USD Billion)
7.18.3 BY INDICATION, 2025-2035 (USD Billion)
7.18.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
7.18.5 BY PRODUCT SOURCE, 2025-2035 (USD Billion)
7.19 Thailand MARKET SIZE ESTIMATES; FORECAST
7.19.1 BY PROBIOTIC FORMULATION TYPE, 2025-2035 (USD Billion)
7.19.2 BY TARGET PATIENT GROUP, 2025-2035 (USD Billion)
7.19.3 BY INDICATION, 2025-2035 (USD Billion)
7.19.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
7.19.5 BY PRODUCT SOURCE, 2025-2035 (USD Billion)
7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST
7.20.1 BY PROBIOTIC FORMULATION TYPE, 2025-2035 (USD Billion)
7.20.2 BY TARGET PATIENT GROUP, 2025-2035 (USD Billion)
7.20.3 BY INDICATION, 2025-2035 (USD Billion)
7.20.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
7.20.5 BY PRODUCT SOURCE, 2025-2035 (USD Billion)
7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST
7.21.1 BY PROBIOTIC FORMULATION TYPE, 2025-2035 (USD Billion)
7.21.2 BY TARGET PATIENT GROUP, 2025-2035 (USD Billion)
7.21.3 BY INDICATION, 2025-2035 (USD Billion)
7.21.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
7.21.5 BY PRODUCT SOURCE, 2025-2035 (USD Billion)
7.22 South America MARKET SIZE ESTIMATES; FORECAST
7.22.1 BY PROBIOTIC FORMULATION TYPE, 2025-2035 (USD Billion)
7.22.2 BY TARGET PATIENT GROUP, 2025-2035 (USD Billion)
7.22.3 BY INDICATION, 2025-2035 (USD Billion)
7.22.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
7.22.5 BY PRODUCT SOURCE, 2025-2035 (USD Billion)
7.23 Brazil MARKET SIZE ESTIMATES; FORECAST
7.23.1 BY PROBIOTIC FORMULATION TYPE, 2025-2035 (USD Billion)
7.23.2 BY TARGET PATIENT GROUP, 2025-2035 (USD Billion)
7.23.3 BY INDICATION, 2025-2035 (USD Billion)
7.23.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
7.23.5 BY PRODUCT SOURCE, 2025-2035 (USD Billion)
7.24 Mexico MARKET SIZE ESTIMATES; FORECAST
7.24.1 BY PROBIOTIC FORMULATION TYPE, 2025-2035 (USD Billion)
7.24.2 BY TARGET PATIENT GROUP, 2025-2035 (USD Billion)
7.24.3 BY INDICATION, 2025-2035 (USD Billion)
7.24.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
7.24.5 BY PRODUCT SOURCE, 2025-2035 (USD Billion)
7.25 Argentina MARKET SIZE ESTIMATES; FORECAST
7.25.1 BY PROBIOTIC FORMULATION TYPE, 2025-2035 (USD Billion)
7.25.2 BY TARGET PATIENT GROUP, 2025-2035 (USD Billion)
7.25.3 BY INDICATION, 2025-2035 (USD Billion)
7.25.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
7.25.5 BY PRODUCT SOURCE, 2025-2035 (USD Billion)
7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST
7.26.1 BY PROBIOTIC FORMULATION TYPE, 2025-2035 (USD Billion)
7.26.2 BY TARGET PATIENT GROUP, 2025-2035 (USD Billion)
7.26.3 BY INDICATION, 2025-2035 (USD Billion)
7.26.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
7.26.5 BY PRODUCT SOURCE, 2025-2035 (USD Billion)
7.27 MEA MARKET SIZE ESTIMATES; FORECAST
7.27.1 BY PROBIOTIC FORMULATION TYPE, 2025-2035 (USD Billion)
7.27.2 BY TARGET PATIENT GROUP, 2025-2035 (USD Billion)
7.27.3 BY INDICATION, 2025-2035 (USD Billion)
7.27.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
7.27.5 BY PRODUCT SOURCE, 2025-2035 (USD Billion)
7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST
7.28.1 BY PROBIOTIC FORMULATION TYPE, 2025-2035 (USD Billion)
7.28.2 BY TARGET PATIENT GROUP, 2025-2035 (USD Billion)
7.28.3 BY INDICATION, 2025-2035 (USD Billion)
7.28.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
7.28.5 BY PRODUCT SOURCE, 2025-2035 (USD Billion)
7.29 South Africa MARKET SIZE ESTIMATES; FORECAST
7.29.1 BY PROBIOTIC FORMULATION TYPE, 2025-2035 (USD Billion)
7.29.2 BY TARGET PATIENT GROUP, 2025-2035 (USD Billion)
7.29.3 BY INDICATION, 2025-2035 (USD Billion)
7.29.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
7.29.5 BY PRODUCT SOURCE, 2025-2035 (USD Billion)
7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST
7.30.1 BY PROBIOTIC FORMULATION TYPE, 2025-2035 (USD Billion)
7.30.2 BY TARGET PATIENT GROUP, 2025-2035 (USD Billion)
7.30.3 BY INDICATION, 2025-2035 (USD Billion)
7.30.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
7.30.5 BY PRODUCT SOURCE, 2025-2035 (USD Billion)
7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.31.1
7.32 ACQUISITION/PARTNERSHIP
7.32.1

Certified Researchers

Customize Report

Food, Beverages & Nutrition Market Segmentation

Food, Beverages & Nutrition By Probiotic Formulation Type (USD Billion, 2025-2035)

Capsules
Powder
Liquid
Soft Chew
Probiotic Yogurt

Food, Beverages & Nutrition By Target Patient Group (USD Billion, 2025-2035)

Infants
Adults
Elderly
Immunocompromised Patients
Patients with Gastrointestinal Disorders

Food, Beverages & Nutrition By Indication (USD Billion, 2025-2035)

Antibiotic-Associated Diarrhea
Irritable Bowel Syndrome
Clostridium difficile Infection
Inflammatory Bowel Disease
General Gut Health

Food, Beverages & Nutrition By Distribution Channel (USD Billion, 2025-2035)

Hospitals
Nursing Homes
Pharmacies
Online Retail
Healthcare Facilities

Food, Beverages & Nutrition By Product Source (USD Billion, 2025-2035)

Bacterial Strains
Yeast Strains
Synbiotics
Fermented Foods

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”

Rob Kooiker Group Product Manager HVAC & Fire Protection GMA

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

Features	License Type
Features	Single User	Multiuser License	Enterprise User
Price	$4,950	$5,950	$7,250
Maximum User Access Limit	1 User	Upto 10 Users	Unrestricted Access Throughout the Organization
Free Customization	✓	✓	✓
Direct Access to Analyst	✓	✓	✓
Deliverable Format	✓	✓	✓
Platform Access	✗	✗	✓
Discount on Next Purchase	10%	15%	15%
Printable Versions	✗	✗	✓